Drugdocs | Olinvyk®

Drug updated on 4/17/2024

Dosage Form	Injection (intravenous: 1 mg/mL, 2 mg/2 mL, 30 mg/30 mL)
Drug Class	Opioid agonists
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Oliceridine (Olinvyk) is indicated for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
A systematic review and meta-analysis was conducted on one document that evaluated the efficacy and safety of oliceridine in patients with postoperative pain.
The study found that a higher proportion of patients responded significantly to oliceridine compared to placebo, showing its effectiveness as a postoperative analgesic.
When comparing oliceridine's effects with morphine, it was observed that both had similar levels of treatment response and analgesia effects; however, fewer respiratory safety events were reported with oliceridine use than morphine use.
Despite its benefits, adverse events such as nausea and vomiting were more frequently associated with Olinerivide (Olinvyk) than placebo.
Overall, despite some adverse events like nausea or vomiting being more common compared to placebos, the safety profile of Olinerivide (Olinvyk) was deemed superior to Morphine making it a viable option for managing severe acute pain where other treatments have proven inadequate.

Document Title	Year	Source
Olinvyk (oliceridine) Prescribing Information.	2021	Trevena, Inc., Chesterbrook, PA

Document Title	Year	Source
Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials.	2023	Expert review of clinical pharmacology